Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 6/2013

01-12-2013 | Research Article

Survey of oral chemotherapy safety and adherence practices of hospitals in Spain

Authors: David Conde-Estévez, Esther Salas, Joan Albanell

Published in: International Journal of Clinical Pharmacy | Issue 6/2013

Login to get access

Abstract

Background Oral chemotherapy is increasingly used for cancer therapy but, without proper practices, creates safety and adherence issues. However, little is known on safety and adherence practices in wide clinical settings. Objective To assess the implementation level of safety and adherence practices in oral chemotherapy in Spanish hospitals. Setting All Pharmacy services from prescription, dispensation, patient education and monitoring hospitals that prescribe oral chemotherapy of Spain. Main outcome measure Level of safety practices regarding oral chemotherapy prescription, dispensation, patient education and adherence. Method An 11 multiple-choice-item questionnaire made in consensus with GEDEFO (Spanish Group of Oncology Pharmacists) was sent to all pharmacy services from hospitals that prescribe oral chemotherapy. This questionnaire comprised prescription, dispensation, education and monitoring. We arbitrarily defined three levels of practices: no sufficient specific practices were reported (we termed this as ‘level I’); performance of an initial visit with a pharmacist providing written patient educational materials and monitoring adherence (termed as ‘level II’); and level II requirements plus electronic chemotherapy ordering system and extra safety practices (termed as ‘level III’). Results Of the 169 targeted health-care settings, 86 (50.9 %) responded to the survey. The majority of responding hospitals were public, general, and teaching hospitals with more than 200 beds. Main discrepancies were in electronic prescription of oral chemotherapy and monitoring adherence. There were 32 hospitals (37.2 %) with level I of safety and adherence practices, 38 hospitals (44.2 %) accomplished level II, 16 (18.6 %) hospitals reached level III. No hospital variables were found to be correlated with each level of safety. Conclusions The majority of responding hospitals have safety and adherences practices for oral chemotherapy. However, the level of these practices varies. There are significant opportunities for improvement, particularly with regard to electronic prescription of oral chemotherapy and monitoring adherence.
Appendix
Available only for authorised users
Literature
1.
go back to reference O’Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002;87:933–7.PubMedCrossRef O’Neill VJ, Twelves CJ. Oral cancer treatment: developments in chemotherapy and beyond. Br J Cancer. 2002;87:933–7.PubMedCrossRef
2.
go back to reference Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(Suppl 3):S1–14.PubMed Weingart SN, Brown E, Bach PB, Eng K, Johnson SA, Kuzel TM, et al. NCCN Task Force Report: oral chemotherapy. J Natl Compr Canc Netw. 2008;6(Suppl 3):S1–14.PubMed
3.
go back to reference Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, et al. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J Clin Oncol. 2009;27:6052–69.PubMedCrossRef Petrelli NJ, Winer EP, Brahmer J, Dubey S, Smith S, Thomas C, et al. Clinical Cancer Advances 2009: major research advances in cancer treatment, prevention, and screening–a report from the American Society of Clinical Oncology. J Clin Oncol. 2009;27:6052–69.PubMedCrossRef
4.
go back to reference Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.PubMed Liu G, Franssen E, Fitch MI, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–5.PubMed
5.
go back to reference Catania C, Didier F, Leon ME, Sbanotto A, Mariani L, Nole F, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat. 2005;92:265–72.PubMedCrossRef Catania C, Didier F, Leon ME, Sbanotto A, Mariani L, Nole F, et al. Perception that oral anticancer treatments are less efficacious: development of a questionnaire to assess the possible prejudices of patients with cancer. Breast Cancer Res Treat. 2005;92:265–72.PubMedCrossRef
6.
go back to reference Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer. 2008;62:85–91.PubMedCrossRef Jensen LH, Osterlind K, Rytter C. Randomized cross-over study of patient preference for oral or intravenous vinorelbine in combination with carboplatin in the treatment of advanced NSCLC. Lung Cancer. 2008;62:85–91.PubMedCrossRef
7.
go back to reference Weingart SN, Toro J, Spencer J, Duncombe D, Gross A, Bartel S, et al. Medication errors involving oral chemotherapy. Cancer. 2010;116:2455–64.PubMed Weingart SN, Toro J, Spencer J, Duncombe D, Gross A, Bartel S, et al. Medication errors involving oral chemotherapy. Cancer. 2010;116:2455–64.PubMed
8.
go back to reference Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia. Spain. Br J Cancer. 2012;107:1249–56.CrossRef Font R, Espinas JA, Gil-Gil M, Barnadas A, Ojeda B, Tusquets I, et al. Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia. Spain. Br J Cancer. 2012;107:1249–56.CrossRef
9.
go back to reference Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–37.PubMedCrossRef Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126:529–37.PubMedCrossRef
10.
go back to reference Dooley M, Carrington C. Recommendations for managing patients receiving oral chemotherapy and target therapies. Asia Pac J Clin Oncol. 2008;4:122.CrossRef Dooley M, Carrington C. Recommendations for managing patients receiving oral chemotherapy and target therapies. Asia Pac J Clin Oncol. 2008;4:122.CrossRef
11.
go back to reference ISOPP standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract. 2007;13(Suppl):1–81. ISOPP standards of practice. Safe handling of cytotoxics. J Oncol Pharm Pract. 2007;13(Suppl):1–81.
12.
go back to reference Jacobson JO, Polovich M, Gilmore TR, Schulmeister L, Esper P, Lefebvre KB, et al. Revisions to the 2009 american society of clinical oncology/oncology nursing society chemotherapy administration safety standards: expanding the scope to include inpatient settings. J Oncol Pract. 2012;8:2–6.PubMedCrossRef Jacobson JO, Polovich M, Gilmore TR, Schulmeister L, Esper P, Lefebvre KB, et al. Revisions to the 2009 american society of clinical oncology/oncology nursing society chemotherapy administration safety standards: expanding the scope to include inpatient settings. J Oncol Pract. 2012;8:2–6.PubMedCrossRef
13.
go back to reference Carrington C, Stone L, Koczwara B, Searle C, Siderov J, Stevenson B, et al. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia Pac J Clin Oncol. 2010;6:220–37.PubMedCrossRef Carrington C, Stone L, Koczwara B, Searle C, Siderov J, Stevenson B, et al. The Clinical Oncological Society of Australia (COSA) guidelines for the safe prescribing, dispensing and administration of cancer chemotherapy. Asia Pac J Clin Oncol. 2010;6:220–37.PubMedCrossRef
14.
go back to reference Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A, et al. Medication safety in the ambulatory chemotherapy setting. Cancer. 2005;104:2477–83.PubMedCrossRef Gandhi TK, Bartel SB, Shulman LN, Verrier D, Burdick E, Cleary A, et al. Medication safety in the ambulatory chemotherapy setting. Cancer. 2005;104:2477–83.PubMedCrossRef
15.
go back to reference Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000:CD000336. Beney J, Bero LA, Bond C. Expanding the roles of outpatient pharmacists: effects on health services utilisation, costs, and patient outcomes. Cochrane Database Syst Rev. 2000:CD000336.
16.
go back to reference SHPA Standards of Practice for the Provision of Oral Chemotherapy for the Treatment of Cancer. J Pharm Pract Res. 2007; 37:149–52. SHPA Standards of Practice for the Provision of Oral Chemotherapy for the Treatment of Cancer. J Pharm Pract Res. 2007; 37:149–52.
17.
go back to reference Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007;334:407.PubMedCrossRef Weingart SN, Flug J, Brouillard D, Morway L, Partridge A, Bartel S, et al. Oral chemotherapy safety practices at US cancer centres: questionnaire survey. BMJ. 2007;334:407.PubMedCrossRef
18.
go back to reference Bonal J, Castro I, Duran J. Trends in clinical pharmacy in Spain. Ann Pharmacother. 1980;14:259–65. Bonal J, Castro I, Duran J. Trends in clinical pharmacy in Spain. Ann Pharmacother. 1980;14:259–65.
19.
go back to reference Colomer R, Alba E, Gonzalez-Martin A, Paz-Ares L, Martin M, Llombart A, et al. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol. 2010;21:195–8.PubMedCrossRef Colomer R, Alba E, Gonzalez-Martin A, Paz-Ares L, Martin M, Llombart A, et al. Treatment of cancer with oral drugs: a position statement by the Spanish Society of Medical Oncology (SEOM). Ann Oncol. 2010;21:195–8.PubMedCrossRef
20.
go back to reference Collins CM, Elsaid KA. Using an enhanced oral chemotherapy computerized provider order entry system to reduce prescribing errors and improve safety. Int J Qual Health Care. 2011;23:36–43.PubMedCrossRef Collins CM, Elsaid KA. Using an enhanced oral chemotherapy computerized provider order entry system to reduce prescribing errors and improve safety. Int J Qual Health Care. 2011;23:36–43.PubMedCrossRef
21.
go back to reference Keely JL. American College of Physicians-American Society of Internal M. Pharmacist scope of practice. Ann Intern Med. 2002;136:79–85.PubMedCrossRef Keely JL. American College of Physicians-American Society of Internal M. Pharmacist scope of practice. Ann Intern Med. 2002;136:79–85.PubMedCrossRef
22.
go back to reference Alminana M. Mangues Bafalluy MA, Santos Ramos B [Spanish presence in BPS accreditation]. Farm Hosp. 2010;34:314–6.PubMedCrossRef Alminana M. Mangues Bafalluy MA, Santos Ramos B [Spanish presence in BPS accreditation]. Farm Hosp. 2010;34:314–6.PubMedCrossRef
23.
go back to reference Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health-Syst Pharm. 2007;64:S4–7.PubMedCrossRef Aisner J. Overview of the changing paradigm in cancer treatment: oral chemotherapy. Am J Health-Syst Pharm. 2007;64:S4–7.PubMedCrossRef
24.
go back to reference Simchowitz B, Shiman L, Spencer J, Brouillard D, Gross A, Connor M, et al. Perceptions and experiences of patients receiving oral chemotherapy. Clin J Oncol Nurs. 2010;14:447–53.PubMedCrossRef Simchowitz B, Shiman L, Spencer J, Brouillard D, Gross A, Connor M, et al. Perceptions and experiences of patients receiving oral chemotherapy. Clin J Oncol Nurs. 2010;14:447–53.PubMedCrossRef
25.
go back to reference Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66.PubMedCrossRef Ruddy K, Mayer E, Partridge A. Patient adherence and persistence with oral anticancer treatment. CA Cancer J Clin. 2009;59:56–66.PubMedCrossRef
26.
go back to reference Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–61.PubMedCrossRef Partridge AH, Avorn J, Wang PS, Winer EP. Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst. 2002;94:652–61.PubMedCrossRef
28.
go back to reference Voeffray M, Pannatier A, Stupp R, Fucina N, Leyvraz S, Wasserfallen JB. Effect of computerisation on the quality and safety of chemotherapy prescription. Qual Saf Health Care. 2006;15:418–21.PubMedCrossRef Voeffray M, Pannatier A, Stupp R, Fucina N, Leyvraz S, Wasserfallen JB. Effect of computerisation on the quality and safety of chemotherapy prescription. Qual Saf Health Care. 2006;15:418–21.PubMedCrossRef
Metadata
Title
Survey of oral chemotherapy safety and adherence practices of hospitals in Spain
Authors
David Conde-Estévez
Esther Salas
Joan Albanell
Publication date
01-12-2013
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 6/2013
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-013-9858-9

Other articles of this Issue 6/2013

International Journal of Clinical Pharmacy 6/2013 Go to the issue